Exchanged that they were looking at the viability of the company in the long term after shares were suspended on the exchange.

In a statement they said: "ImuMed International Ltd. is currently in negotiations with various sources in respect of financing opportunities which may be available to the company. Discussions are also in progress with creditors to ensure the viability of the company's activities in the longer term.

"In these circumstances, the directors have requested that the present suspension should be extended pending the potential recovery of ImuMed Deutschland GmbH (Antitoxin), together with its subsidiaries, Antitoxin Dr.

Helmbold GmbH, Institut fur Immuntherapie Antitoxin Verwaltungs GmbH and Institut fur Immuntherapie Antitoxin GmbH & Co. KG, from bankruptcy proceedings in Germany.''